Validity Testing Information Part I

Laboratory Name: DRUGPROOF Division of DYNACARE
Address: 1229 Madison Suite 500 Seattle, WA 98104

Responsible Person: Arthur M Zebelman, Ph.D. (Printed Name)

I certify that the answers and information provided are true and correct as of this date. Any false, fictitious, or fraudulent answers or information provided may violate Federal Law and could subject me to prosecution, monetary penalties, or both (Sec 18 U.S.C. 1001; 31 U.S.C. 3801-812).

Signature, Responsible Person

10/3/00
Date

ARTHUR M ZEBELMAN
Printed Name, Responsible Person

Validity Testing Information Part II

Conduct an audit of all DOT regulated specimens from the date your laboratory started validity testing. Summarize your findings in an Excel spread sheet in both hard copy and electronic format. Provide the following information in a separate column of the spreadsheet/audit for *each* DOT regulated specimen that was reported either adulterated or substituted:

- **Specimen ID number**
- **Laboratory Accession Number**
- **Date of receipt**
- **Date reported**
- **Reported result (i.e., adulterated or substituted)**
- **Quantitative test result (e.g., actual creatinine concentration and specific gravity reading; actual pH reading; adulterant identity and its concentration if applicable)**

Note: Retain a copy of this information to ensure that you would be able to retrieve additional data.

I certify that the answers and information provided are true and correct as of this date. Any false, fictitious, or fraudulent answers or information provided may violate Federal Law and could subject me to prosecution, monetary penalties, or both (Sec 18 U.S.C. 1001; 31 U.S.C. 3801-812).

aH-RP
Signature, Responsible Person

10-4-00
Date

Gregory L. Randall
Printed Name, Responsible Person

DRUGPROOF Division of Dynacare Laboratories Lab#032

SpecimenID	Accession #	Received Date	Report Date	REPORTED	ADULTERANT	ADULT QUANT	CREATININE	SPECIFIC GRAVITY

Lab 32SVtaudit.x

Substituted and Adulterated Specimens

DRUGPROOF Division of Dynacare Laboratories Lab#032

SpecimenID	Accession #	Received Date	Report Date	REPORTED	ADULTERANT	ADULT QUANT	CREATININE	SPECIFIC GRAVITY

RESEARCH TRIANGLE INSTITUTE

National Laboratory Certification Program

November 17, 2000

0032
Dr. Arthur M. Zebelman
Drug Proof, Div. of Dynacare/Lab of Pathology, LLC
1229 Madison St. Suite 500
Nordstrom Medical Tower
Seattle, WA 98104

Dear Dr. Zebelman:

The enclosed critique was developed from the inspection report associated with the October 18, 2000 specimen validity testing inspection of your laboratory under the National Laboratory Certification Program (NLCP). The laboratory's procedures were not in compliance with program guidance issued in Program Document 035 (September 28, 1998) and Program Document 037 (July 28, 1999). The laboratory must submit information to address the following issues raised:

3040 Cornwallis Road • Post Office Box 12194 • Research Triangle Park, North Carolina 27709-2194 USA
Telephone 919 541-6709 • Fax 919 541-7042

The laboratory must submit, within 30 calendar days of receipt of this letter, documentation to demonstrate that corrective actions have been implemented to address the issues raised. In responding to these issues, please organize the material in your document in accordance with the sections and item numbers as listed in this correspondence. The laboratory must also review the enclosed critique and take all necessary corrective actions. All corrective actions must be implemented within 30 days receipt of this correspondence and will be reviewed at the next inspection.

If you have any questions or if we can be of further assistance, please call me at (919) 541-7265 or Dr. Michael Baylor at (919) 541-7043.

Sincerely,

Deborah J. Denson

Deborah J. Denson
NLCP Technical Analyst

Enclosure

cc: Project Files/svt032

NATIONAL LABORATORY CERTIFICATION PROGRAM

Document Review and Critique

Laboratory I.D. Number: 0032
Document No. Final

Laboratory: DrugProof

Location: Seattle, WA

Document Reviewed: [XX] Specimen Validity Testing Inspection Report

Date: 18 October 2000

A review of the National Laboratory Certification Program (NLCP) consensus inspection report has been completed. Issues identified during the inspection are described on the following pages. Evidence that appropriate remedial action has been taken is required for continued certification.

The following comments were noted, and appear in the same order as the corresponding questions in the Laboratory Inspection Report:

Section E. Standard Operating Procedures - Procedures Manual

Section F. Chain-of-Custody, Accessioning, and Security

Section G. Quality Control and Quality Assurance

Section I. Specimen Validity Tests

Section K. Records Audit



Section L. Certification and Reporting

DRUG PROOF®
flexible service | rigid procedures

received
11/30/00 DD

1229 Madison Street | Suite 500 | Seattle, WA 98104
Tel 206.386.2661 • 800.898.0180 | Fax 206.386.2436

November 29, 2000

Deborah J. Denson
NLCP Technical Analyst
Research Triangle Institute
3040 Cornwallis Road
Research Triangle Park, NC 27709

Dear Ms. Denson:

This correspondence documents the corrective actions taken in response to the critique associated with the October 18-20, 2000 specimen validity testing inspection of this laboratory. The response is organized in accordance with the sections an item numbers listed in your letter of November 17, 2000.

If you have further questions regarding these issues, please call me at 206-386-2438 or send e-mail to **azebelman@dynacare.com**.

Sincerely,



Arthur M. Zebelman, Ph.D.
Responsible Person

RESEARCH TRIANGLE INSTITUTE

National Laboratory Certification Program

December 12, 2000

0032
Dr. Arthur M. Zebelman
Drug Proof, Div. of Dynacare/Lab of Pathology, LLC
1229 Madison St. Suite 500
Nordstrom Medical Tower
Seattle, WA 98104

Dear Dr. Zebelman:

We have reviewed the material provided in your correspondence of November 29, 2000 submitted in response to issues raised during the October 18, 2000 specimen validity testing inspection of your laboratory as outlined in our correspondence of November 17, 2000. The information submitted by the laboratory appears to demonstrate that appropriate corrective actions have been completed to address the issues raised. However, the following issue requires additional corrective action:

Based upon our review of the material submitted, it appears that the laboratory is taking steps to ensure that its specimen validity testing procedures are in compliance with program guidance. All corrective actions must be implemented within 30 days of the receipt of this correspondence and will be reviewed during the next inspection. Failure to comply may result in the laboratory's suspension to perform specimen validity testing on federally regulated specimens.

If you have any questions or if we can be of further assistance, please call me at (919) 541-7265 or Dr. Michael R. Baylor at (919) 541-7043.

Sincerely,

Deborah J. Denson

Deborah J. Denson
NLCP Technical Analyst

cc: Project Files/SVT0032

3040 Cornwallis Road • Post Office Box 12194 • Research Triangle Park, North Carolina 27709-2194 USA
Telephone 919 541-6709 • Fax 919 541-7042